Phase I Trial of Irinotecan, Infusional 5-Fluorouracil, and Leucovorin (FOLFIRI) With Erlotinib (OSI-774): Early Termination Due to Increased Toxicities

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-04-0746
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Adjuvant Chemoradiation for Gastric Cancer With Infusional 5-Fluorouracil and Cisplatin: A Phase I Study

Current Oncology
Oncology
2010English

5 Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) as a Third-Line Chemotherapy Treatment in Metastatic Gastric Cancer, After Failure of Fluoropyrimidine, Platinum, Anthracycline, and Taxane

Bosnian Journal of Basic Medical Sciences
Medicine
2017English

Celecoxib and Mucosal Protection: Translation From an Animal Model to a Phase I Clinical Trial of Celecoxib, Irinotecan, and 5-Fluorouracil

Clinical Cancer Research
Cancer ResearchOncology
2007English

Liposomal Irinotecan and 5-Fluorouracil/Leucovorin in Older Patients With Metastatic Pancreatic Cancer – A Subgroup Analysis of the Pivotal NAPOLI-1 Trial

Journal of Geriatric Oncology
GerontologyGeriatricsOncology
2019English

Quality of Life in Metastatic Pancreatic Cancer Patients Receiving Liposomal Irinotecan Plus 5-Fluorouracil and Leucovorin

European Journal of Cancer
Cancer ResearchOncology
2019English

Southwest Oncology Group Phase II Trial (S0341) of Erlotinib (OSI-774) in Patients With Advanced Non-Small Cell Lung Cancer and a Performance Status of 2

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2008English

A Phase I Pharmacologic and Pharmacogenetic Trial of Sequential 24-Hour Infusion of Irinotecan Followed by Leucovorin and a 48-Hour Infusion of Fluorouracil in Adult Patients With Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2005English

Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2016English

Serum Iron Levels as a New Biomarker in Chemotherapy With Leucovorin and Fluorouracil Plus Oxaliplatin or Leucovorin and Fluorouracil Plus Irinotecan, With or Without Molecularly-Targeted Drugs

Molecular and Clinical Oncology
Cancer ResearchOncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy